Chromosomal translocations are frequently linked to multiple hematological malignancies. The study of the resulting abnormal gene products has led to fundamental advances in the understanding of cancer biology. This is the first report of t(2;15)(p23;q22) and t(2;17)(p23;q21) translocations in human malignancy. Patient 1, a 73-year-old male, was diagnosed with myeloblastic (FAB M1 sub-type) AML. Cytogenetic analysis showed a 47,XY,t(2;15)(p23;q22),+13 karyotype. Fluorescent in situ hybridization (FISH) showed that the PML gene was transferred intact to the short arm of chromosome 2 while the ALK gene on chromosome 2p23 was passively transferred to the long arm of chromosome 15. Patient 2 was a 60-year-old male diagnosed with monocytic (FAB M4-type) AML. Cytogenetic analysis showed 46,XY,t(2;17)(p23;q21) karyotype. FISH analysis showed that neither RAR␣ nor ALK were disrupted by the translocation. None of the coding region of the three genes studied were translocated in these patients. This raises the possibilities that other neighboring genes could be involved or that noncoding regulatory sequences of the studied genes could be put in contact and deregulate expression of other genes. Alternatively, displacement of ALK, RAR␣ and PML to novel positions could lead to loss of their normal regulation
Introduction
Consistent chromosomal translocations associated with specific subtypes of acute leukemia have both diagnostic and prognostic significance. For example, the t(8;21) which fuses the genes ETO/MTG8 and AML-1/CBF␣ is both diagnostic for M2 AML and is a marker for favorable prognosis. [1] [2] [3] Another example is the translocation disrupting the retinoic acid receptor ␣ gene -which is diagnostic for acute promyelocytic leukemia (APL) when fused to loci 15q22, 11q23, 5q35 and 11q13. 4 These regions encode the genes for PML (promyelocytic leukemia), PLZF (promyelocytic leukemia zinc finger), NPM (nucleophosmin) and NuMA (nuclear matrixmitosis associated). APL associated with t(15;17) is uniquely sensitive to treatment with retinoic acid, however, the t(11;17)(q21;q23) translocation predicts for disease that is resistant to this modality. These loci have been uniquely associated with APL and have not been described in any other form of leukemia. We describe two clinical cases of leukemia with novel chromosomal rearrangements involving 15q22 and 17q21 and which did not have the phenotype of APL. Interestingly, both of these loci were re-located to the short arm of chromosome 2. This area contains the ALK (anaplastic lymphoma kinase) gene -which is involved in anaplastic large cell lymphoma associated with a translocation between chromosomes 2 and 5. 
Case reports

Patient 1
A previously healthy 73-year-old male, presented in June 1996 with acute myeloblastic leukemia (FAB M1 sub-type). The patient was treated with standard induction chemotherapy consisting of cytosine arabinoside and idarubicin and achieved complete remission. He subsequently underwent one cycle of consolidation chemotherapy with cytosine arabinoside and remained in complete remission. In December of 1996 he was noted to be leukopenic with blasts noted in the peripheral smear. Relapse of AML was diagnosed and a second course of identical induction chemotherapy was administered but this time without response. A bone marrow biopsy and aspirate revealed a hypercellular bone marrow with 20% myeloblasts -consistent with the RAEB (refractory anemia with excess blasts) variety of myelodysplasia. Cytogenetic analysis in all 30 metaphases studied showed a 47,XY,t(2;15)(p23;q22),+13 karyotype. The patient subsequently had a rapid increase in his leukocyte count and replacement of the bone marrow with a monomorphic infiltrate of blasts, and died shortly thereafter.
Patient 2
A 60-year-old male presented in December 1996 with fatigue, weight loss, dyspnea and hemoptysis for several weeks. There was an acute loss of strength of the right upper and lower extremities. The patient had a previous history of bladder polyps, chronic pulmonary disease as well as heavy smoking and alcohol use. He had thrombocytopenia, macrocytic anemia and generalized lymphadenopathy as well as a granulocyte count of 150 000/l. A bone marrow study revealed a hypercellular marrow with 70% blasts. Morphologic and cytochemical analysis was consistent with monoblastic (FAB M4-type) AML. Cytogenetic analysis showed a 46,XY,t(2;17)(p23;q21) karyotype. The patient was then treated with standard induction chemotherapy consisting of cytosine arabinoside and idarubicin, however, there was no response to treatment and he died shortly after.
Materials and methods
Cytogenetics
Chromosomes were obtained from bone marrow cells using previously described methods.
5 ISCN (1995) nomenclature was used to describe the karyotypes.
Fluorescence in situ hybridization (FISH)
An aliquot of cytogenetic cell suspension was used for FISH studies. Slides were denatured at 75°C for 5 min in 60% formimide/2 × SSC and hybridized overnight with a dual color PML-RAR␣ probe (Vysis, Downers Grove, IL, USA) as well as with two ALK probes (obtained as gifts from Dr Steve Morris and from Vysis). Post-hybridization washings were according to the manufacturer's instructions. Two hundred ng of ALK probe was used for hybridization and post-hybridization washings were the same as for PML-RAR␣. Metaphase chromosomes were counterstained with 4Ј,6-diamidino-2-phenylindole (DAPI). In addition to the above, for patient 1, a probe for the PML 3Ј non-coding sequences were used (obtained as a gift from Vysis). For patient, 2 RAR␣ 3Ј and 5Ј probes labeled in different colors were used (Vysis). Images of chromosomes for both patients were taken using Zeiss microscope connected to a Cytovision System (Applied Imaging, Pittsburgh, PA, USA).
Results
All 30 evaluated metaphases from patient 1 showed rearrangements between the short arm of chromosome 2 and long arm of chromosome 15 as well as trisomy 13. The karyotype was 47,XY,t(2;15)(p23;q22),+13. All 50 evaluated metaphases from patient 2 showed rearrangements between the short arm of chromosome 2 and the long arm of 17. The karyotype was 46,XY,t(2;17)(p23;q21). The nature of these translocations, involving loci usually associated with APL, led us to perform gene mapping to further evaluate the origin of these rearrangements. Metaphase FISH studies were performed to detect possible disruptions of PML, RAR␣ and ALK. Additional FISH studies demonstrated a reciprocal translocation of intact ALK from 2p23 to the deleted chromosome 15 using the 3Ј PML probe. In this case, the RAR␣ gene was unaffected by the translocation. Figure 2 shows translocation 2;17 from patient 2 and relocation of both the 3Ј and 5Ј portion of the intact RAR␣ gene to chromosome 2. The fact that both probes co-localize on chromosome 2 rules out any possible internal breakpoints in the coding regions of RAR␣. If such a breakpoint did occur, there would be separation of the red and green hybridization signals on chromosome 2. FISH studies with dual color PML (red)/RAR␣ (green) revealed the normal localization of PML on chromosome 15q22.
Discussion
We identified two novel translocations, t(2;15)(p23;q22) and t(2;17)(p23;q21) in the setting of acute myelogenous leukemia. The breakpoints involved in these rearrangements are localized to the 2p23, 15q22 and 17q21 loci. These translocations involve regions which are known to be rearranged in other hematologic malignancies but never in this pattern. Indeed, to our knowledge, this is the first report of these translocations in any hematologic malignancy.
The 17q21 locus is the site of a number of gene products. Prominent among these is the RAR␣ gene product. 7 RAR␣ is rearranged as a fusion product in acute promyelocytic leukemia 4 most commonly with the PML gene which is located on chromosome 15q22. RAR␣ is upregulated during commitment to the myeloid lineage and may regulate the expression of a large host of genes critical to the myeloid phenotype. 4 Such targets include neutrophil granule proteins, cell surface adhesion molecules, colony-stimulating factors, colony-stimulating factor receptors, cytokines, etc. 4 Understanding the biology and mechanism of action of RAR␣ fusion proteins resulted in highly successful novel therapeutic approaches which directly target the molecular mechanisms of leukemogenesis in acute promyelocytic leukemia. 4 To determine whether the RAR␣ gene was involved in patient 2, we performed FISH assays, which demonstrated that
Figure 2
A partial karyotype from patient 2 showing t(2;17). RARA (green) from chromosome 17 was translocated to chromosome 2 after FISH studies utilizing dual color PML-RARA probes (left panel from the idiogram). The right panel shows der(2)t(2;17) and normal chromosome 17 after metaphase FISH utilizing dual color 5ЈRARA (red)/3ЈRARA (green). Any breakpoint in RARA gene will cause the separation of green and red hybridization signal. The observation that green and red signals are fused resulting in a yellow hybridization signal strongly suggests that RARA gene was intact when translocated to chromosome 2.
RAR␣ was not disrupted. In light of the fact that RAR␣ disruption appears to be responsible for the promyelocytic phenotype of APL cells 8 this is not a surprising finding. Indeed, expression of dominant negative forms of RAR␣ in hematopoietic cells, or the even the forced overexpression of wild-type RAR␣, result in differentiation block at the promyelocyte stage of development. This may be due to sequestration of RAR␣ partner protein RXR, thus inhibiting proper interaction of these proteins with their target promoters. 4 Consistent with the observed non-involvement of RAR␣, this patient had a non-APL phenotype and was classified as M4 AML.
However, it is possible that the disruption of 17q21 resulted in the disturbance of other genes. Several other gene products from this area are linked to human malignancies. One of these is the familial breast-ovarian cancer BRCA1 gene, 9 a tumor suppressor which may be involved in DNA repair and transcriptional regulation. 10, 11 A number of other genes critical for cellular differentiation and growth are located at 17q21. 12 These include:
• The HOXB cluster of homeotic proteins, 12 several of which are involved in hematopoietic cell differentiation. 13 In addition, murine models show that forced overexpression of certain HOXB genes can lead to proliferation of hematopoietic progenitor cells and, in the case of HOXB8, to late onset AML. 13 • The chromatin remodeling and transcriptional machinery adapter proteins GCN5L2 and TADA2L. 14, 15 Recent reports have demonstrated that deregulation of proteins such as transcriptional co-activators, co-repressors, histone acetylases and histone deacetylases, is an important mechanism in several types of leukemia. For example, the interaction of chimeric proteins resulting from translocations found in APL and t(8;21) M2 AML with these chromatin remodeling mediators may be central to their pathogenic role 4, 16, 17 and indicates a common pathway of leukemogenesis.
• The E1A-F transcription factor gene, which induces proteins involved in invasion and metastasis such as matrix metalloproteinases, and is upregulated in invasive cancer. [18] [19] [20] [21] [22] [23] E1A-F is targeted for translocation in the certain cases of childhood sarcomas. 24, 25 • The cdc6 cell cycle regulatory protein 26, 27 which has a key role in DNA replication during S phase.
• Numerous others, including hox-like genes, other transcription factors and signaling transduction pathway mediators. 12 It is interesting to speculate whether any of these genesmany of which may be involved in mechanisms governing cellular differentiation, cycling and growth -could be partly responsible for the leukemic properties of this patient's cells.
The PML (promyelocytic leukemia) gene localized on chromosome 15q22 is the fusion partner of RAR␣ in more than 90% of APL patients. 4 PML localizes to specific subnuclear structures know as nuclear bodies which are disrupted in APL and in viral infections. 4 Multiple functions have been assigned to PML, such as roles in apoptosis, growth suppression, immune response pathways as well as the transcriptional and post-transcriptional regulation of gene expression. 4, 28, 29 Furthermore, observations in PML null mice strongly suggest a tumor suppressor function for PML. For example, these animals had double the incidence of lymphomas when treated systemically with the chemical tumor initiator DMBA as compared to control mice. 29 FISH performed on the leukemic cells from patient 1 revealed that the PML locus was intact in this patient. Therefore it is highly probable that a different gene product is targeted in the 15q22 regions.
Several other genes interesting from the leukemia point of view are also present on 15q22. Prominent among these is the MEK1 gene.
30 MEK1 forms part of the MAP kinase signal transduction cascade, can induce cellular transformation when mutated and is functionally linked to the cell cycle. [31] [32] [33] To date, MEK1 has not been found to be rearranged or mutated in AML. Also located at 15q22 is the Tle-3 gene, a member of the notch signaling pathway. 34 Mutations of notch pathway members (although not Tle-3) have been demonstrated in T cell acute lymphoblastic leukemia. 35 Another notch pathway gene, the metalloprotease-disintegrin kuz, also localizes to this locus. 36 Kuz is overexpressed in certain neoplasias and is involved in cleaving notch ligand precursors located on the cell surface. 36, 37 Finally, the ERC-55 gene codes an endoplasmic reticulum-associated protein which binds to the papillomavirus E6 oncoprotein. 38, 39 Both of our patients harbored rearrangements affecting the 2p23 locus. This band region is a well known target for disruption in different leukemias. Previously reported translocations involving this locus include:
• t(2;4)(p23;q25), t(2;4)(p23;q31), t(2;4)(p23;q35) and t(2;3)(p23;q26) in M2 acute myelogenous leukemia.
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• t(2;5)(p23;q35) in the setting of chromic eosinophilic leukemia. 44 • Deletion(2)(p23) either as solitary or complex abnormalities in primary and secondary AML. [45] [46] [47] Thus, disruption of chromosome 2 at the p23 locus appears to be a recurring genetic lesion in leukemias. This suggests that one or more as yet undetermined 2p23 genes, when altered by translocation, can disregulate growth control and differentiation of myeloid progenitor cells.
One of the prominent genes at 2p23 is named ALK, 48 a membrane spanning protein tyrosine kinase with homology to LTK (64%), TRKA (38%), ROS (37%), Sevenless (35%), ␤IGF-1(37%) and ␤IR (36%). It forms a chimeric fusion product with the nucleophosmin gene on chromosome 5q35 in the subset of patients with anaplastic large cell lymphoma that harbor the t(2;5)(p23;q35) translocation. 48 We analyzed leukemic cells of both patients using FISH to determine whether ALK was disrupted. In neither case was there any evidence of ALK rearrangements. FRA-2, 49 a fos transcription factor family member, is also localized to this region. Interestingly, fos transcription factors may participate in the differentiation of early hemopoietic cells 50 and may predispose leukemic cells towards differentiation. Thus, it is tempting to speculate that the disruption of a fos gene such as FRA-2 could contribute to the leukemogenic process, either by inactivating the gene via a dominant negative effect or via an aberrant oncogenic gain of function.
Finally, in addition to abnormalities caused by internal disruptions of gene loci, positional effects caused by displacement of regulatory elements to the proximity of heterotopic genes can result in inappropriate expression patterns of proteins, contributing to the transformed state. For example, displacement of the BCL6 transcription factor to the IGH (immunoglobulin heavy chain locus) results in a loss of the normal down-regulation of this protein as B cells exit the germinal center, contributing to the development of diffuse large cell lymphoma. 51 Multiple different translocations fusing the IGH or T cell receptor (TCR) regulatory region loci to mediators of cell survival or proliferation result in B cell and T cell neoplasms. 51 In the same fashion, the normal pattern of expression of the gene products discussed above may be altered by the disruption of surrounding upstream or down-stream regulatory elements. This might result in ectopic expression, overexpression or suppression of one or more of these proteins.
In conclusion, we have described two novel translocations in acute myelogenous leukemia. These translocations involved breakage near loci known to be involved in hematological malignancies and which may have pathophysiologic significance. However, none of these genes were disrupted, suggesting that there are other genes in these chromosomal regions whose translocation could contribute to the transformation of hemopoietic cells into leukemic blasts. Several interesting candidates have been mentioned although there is no evidence that these gene products are altered in these patients. Further investigations of the gene rearrangements at the 2p23, 15q22 and 17q21 loci will undoubtedly yield a greater understanding of the molecular pathogenesis of AML.
